Dr Reddys Laboratories Ltd has settled patent litigation with GlaxoSmithKline relating to sumatriptan succinate tablets, the generic version of GlaxoSmithKline's Imitrex tablets, a company release said.

The terms of the settlement, which remain subject to government review, provide that the company may exclusively distribute an authorized generic version of sumatriptan succinate tablets (in the 25 mg, 50 mg and 100 mg strengths) in the US with an expected launch date late in the fourth quarter of calendar year 2008 ahead of the expiration of the paediatric exclusivity on 5037845 patent on February 06, 2009.

Additional terms of the settlement agreement were not disclosed.

GlaxoSmithKline's Imitrex tablets, which are indicated for the acute treatment of migraine attacks in adults, had US sales of $890 million for the 12 month period ending June 2006 according to IMS.